Capillary isoelectric focusing (clEF) was used to identify
Indexing Terms: hemoglobinopathy/sickle cell disease/thalassemia

Hemoglobins
(Hb) are polypeptide tetramers consisting of two pairs of unlike globin chains (e.g., a, , y, S), each of which is covalently linked to four different heme groups (1 ) 4 Normal adult human Hb is >95% Hb A
(a.2$),
with Hb A2 (a#{244})and Hb F (a'y2) present as minor constituents.
Many congenital and acquired hematologic disorders exist. Congenital defects in Hb synthesis include both abnormal production of normal globin chains (e.g., a-and /3-thalassemia syndromes) and the production of abnormal or variant globin chains such as Hb S and >600 other structurally different were derived from reported values (10, 12) but adjusted to reflect best-fit regression analysis of p1 against the migration times determined by clEF in this laboratory. The p1 of Hb in unknown samples was calculated by the instrument software by fitting the corrected migration time of unknown Hb into the linear regression equation derived from the control. Corrected migration was calculated by using Hb A as a reference peak in each sample.
The instrument software quantifies the results on the basis of peak detection and integration of absorbance at 415 rim, which is specific for the detection for heme moieties. Values are expressed as a percent of total Hb, i.e., the peak area for each Hb divided by the total peak area. The upper limit of the linear range of the detector listed by the manufacturer is 0.2 A. If the height of any peak exceeded this limit, the sample was reanalyzed with a lower injection volume.
AnalyticalVariables
Linearity.
Assay linearity
for Hb A2, S, F, A, and A1 was evaluated with two series of five hemolysates prepared with various volume ratios (100:0, 75:25, 50:50, 25:75, 0:100) of blood from two different subjects, each with predominantly one major Hb variant. One series contained blood from a subject with 13-thalassemia A2, mostly Hb F). The second series contained blood from the same -thalassemia subject and from a subject with sickle cell disease (no Hb A, mostly Hb S). All samples were analyzed in duplicate, and the mean observed values were compared with the expected values by least-squares linear regression analysis. Detection limit. The detection limit was estimated by analyzing variation in baseline absorbance at 415 nm during blank runs (i.e., without sample). A peak height five times greater than the variation in baseline was considered the minimum quantifiable peak height. Relative peak area at this peak height was calculated based on response factors (% of total Hb per unit of peak area) determined by analysis of control materials and was used to estimate the minimum quantifiable amount for any Hb variant. 
Results
HemoglobinIdentificationand Quantitation
Because Hb A represents -90% of the Hb in normal blood, minor constituents are not well-represented in electropherograms shown at full scale. Consequently, the scales of some of the figures presented are expanded to enhance evaluation of minor constituents. All of the clinically important Hb variants present in normal blood were readily identified by clEF, including Hb A2, F, A, and A1 (Fig. 1) sickle cell trait, Hb S/C disease, Hb S/f3#{176}-thalassemia, and $-thalassemia minor. In clEF, as in conventional gel IEF, Hb S migrated between Hb A2 and Hb F and was completely resolved from these two constituents ( Fig. 2A) . Hb C, after Hb S the next most common structural Hb variant, is shown in Fig. 2B . Note that Hb A is not produced in this double heterozygote (Hb C/S) condition, and that Hb C mmgrates slightly cathodic to Hb A2. The proximity of these two variants means that Hb A2 cannot be accurately measured in the presence of Hb C, a problem common among charge-based separation methods. Another double heterozygote condition is Hb S/#{176}-thalassemia (Fig. 2C) , in which one of the two /3-globin genes produces Hb S, whereas a defect in the second gene eliminates 3-globin synthesis by that gene. This complete lack of Hb A production (because of the ab-0.020 (normal range in our patient population, 1.6%-2.8%) and often markedly increased production of Hb F (ordinarily present at <1% in this age group). The syndrome is differentiated from the homozygous Hb S condition by the high proportion of Hb A2 and F, and by evidence of severe anemia, microcytosis, and hypochromia, which are not observed in sickle cell disease.
Another aspect of the high resolving power of clEF that is important for neonatal or prenatal hemoglobinopathy screening is illustrated in this electropherogram (Fig. 2C) . Hb F is a posttranslational modification of Hb F representing -10% of Hb F under normal conditions (12) . In neonates, where the proportion of Hb F is 60%-90% of total Hb, the amounts of Hb A and F present in the blood may be similar (i.e., -10%). Because Hb F comigrates and is not readily differentiated from Hb A by some Hb separation methods, those methods cannot differentiate between the heterozygous Hb A/S and homozygous Hb S/S condition in neonates. In contrast, the absence of Hb A is readily apparent in blood analyzed by clEF (Fig. 2C) clEF for this purpose, and a further demonstration of its resolving power, is illustrated by comparing the analyses of Hb S and D-Los Angeles in two commercial controls (Fig. 3) lack of good separation between Hb A and A10, Hb S was easily identified from other constituents in <4 mm.
Analytical Variables
Linearity. IEF (12, 13, 16, 17) .
Other hemoglobins identified by clEF in this laboratory (data not shown) Multiple assays also require multiple samples, markedly increasing the amount of blood drawn. In contrast, the clEF method described here requires only 10 tL of whole blood to make 210 pL of hemolysate-and this is the full extent of sample preparation.
Using a 20-s low-pressure injection introduces -40 nL of sample into the capillary; thus, the 210 pL of hemolysate is sufficient for several thousand analyses of the specimen.
Low 
